SABCS23 Day 3 Highlights by Oncology Brothers

Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the third day’s highlights from X/Twitter.

”SABCS23 Day 3 Highlights Community Oncology:

1. TROPIONBreast01.
2. Optimizing XRT and Surgery in early BC.
3. Pregnancy after breast ca diagnosis.

1. TROPION Breast01: DatoDXd Vs Chemo post 1-2L in HR+ mBC

– time to 1st Rx: 8.2 vs 5mos (HR: 0.53, favoring Dato),
– Better AE + QoL with DatoDXd,
– higher PFS at ESMO23. Pending OS. Very likely to get approved and be in the same space as Sacituzumab.

For the more information click here.

2. Optimizing Surgery and XRT:

– low staging nodal status (cN+ to ypN0) w/ NACT can optimize adj XRT,
– ALND improved local regional recurrence (but this risk is low to begin with).  mortality benefit. Higher lymphedema,
– XRT can be safely  in HR+ postmenopausal low risk Stage I.

For the more information click here.

3. Pregnancy w/ Breast Cancer diagnosis:

– POSITIVE Ann Partridge: most pts w/ amenorrhea resumed menses when endocrine Rx was interrupted,
– Young age associated w/ shorter time to pregnancy,
– Analysis by Matteo Lambertini showed  low complications even w/gBRCA pts.

For the more information click here.”

Source: Oncology Brothers/X